Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of arformoterol tartrate inhalation solution 30μg/4mL QD
(two 15μg/2mL dosed in combination) over a 24-hour period compared to arformoterol tartrate
inhalation solution 15μg/2 mL BID in subjects with COPD.